Message #20 From:
NewsBot Date: October 30, 2006 06:44:00 AM
CYGX News CytoGenix Gene Silencing ssDNA Technology Patent Allowed in Europe and India
HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (CYGX:OB) has received notices of allowances for
grant of patent applications covering the technology for expressing
ssDNA In Vivo, from the Indian and European Community Patent
Offices. These notices follow the previous notice of allowance for these
applications from the Peoples Republic of China.
Filed in 1999 and 2000, these patents cover the company’s
single-strand DNA expression system covered by a US patent and by
several patent applications in major world markets. Used in the company’s
Simplivir™ anti-herpes and CY303 anti
inflammation products, an ssDNA gene silencing compound is active in
reducing tumors in a melanoma experimental animal model.
Dr. Yin Chen, CytoGenix, Inc. Vice President, Chief Scientific Officer
and a co-inventor of the single-strand DNA expression technology,
states, “This is another step in our
intellectual property strategy for this technology. These countries
offer significant market opportunities and we are seeking appropriate
licensees and partners.”
About CytoGenix, Inc.: CytoGenix, Inc. is a Houston-based
biopharmaceutical company that develops and markets innovative products
and services based on its proprietary ssDNA expression technology. The
company has developed a breakthrough synthetic process for large-scale
production of high purity DNA at a fraction of the cost of traditional
fermentation methods. CytoGenix currently has one issued US patent and
47 international or US pending patent applications claiming methods and
materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology is found on the website at www.cytogenix.com.
